The Mount Sinai Community Clinical Oncology Program is reapplying for CCOP funding to continue and expand the existent programs in cancer treatment and cancer research. Through Mount Sinai, the clinical investigators have access to research labs, abundant inpatient and outpatient facilities, and sophisticated diagnostic and treatment resources. Presently affiliated with NSABP, CALGB and M.D. Anderson Cancer Center, Mount Sinai has affiliated recently with RTOG. The CCOP investigators have the experience, aptitude and interest to participate with these research bases in the development and implementation of protocols, and submission of data for cancer treatment and control research. Continued funding under the CCOP project will assist in maintaining and expanding the data management resources necessary to complete and submit data in a timely manner. There are three major objectives of the Mount Sinai CCOP: 1. Expansion of patient base - the base of operations has been expanded to the area of Dade, Broward and Palm Beach counties. The service area is very large in population and substantially represented by minorities. The Mount Sinai CCOP will continue to serve an area that is growing in overall population and in residents age 65 and over. Affiliations have been established with Holy Cross Hospital (Fort Lauderdale), Memorial Hospital (Hollywood), the South Florida Radiation Oncology Center and CCRGI. More affiliations are planned. 2. Oncology resources - Mount Sinai is devoting more resources and efforts to cancer. Mount Sinai opened an outpatient cancer center in April, 1989 which resulted in the relocation of all medical oncologists to the Mount Sinai site. This Fall, ground will be broken for a new freestanding outpatient facility. Through its work with VMO and other projects, Mount Sinai continues to demonstrate its commitment to research. Further demonstration of the institution's commitment is the development of an autologous bone marrow transplant service which will begin in 1990. 3. Awareness of protocol availability - CCOP protocols are increasingly being used. Mount Sinai plans to strengthen its protocol accession through continued awareness of protocol availability and through the extension of CCOP influence in the three county area. Mount Sinai has been successful in extending its CCOP protocols to area physicians and institutions which have joined Mount Sinai as affiliates.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045564-06
Application #
3558693
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-07-13
Project End
1993-05-31
Budget Start
1992-06-01
Budget End
1993-05-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Mount Sinai Medical Center (Miami Beach)
Department
Type
DUNS #
046025144
City
Miami Beach
State
FL
Country
United States
Zip Code
33140
Apoe, Ogheneruona; Jung, Sin-Ho; Liu, Heshan et al. (2016) Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data. Am J Hematol Oncol 12:4-9
Cushman, Stephanie M; Jiang, Chen; Hatch, Ace J et al. (2015) Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Clin Cancer Res 21:1078-86
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Jeon, Justin; Sato, Kaori; Niedzwiecki, Donna et al. (2013) Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer 12:233-8
Aggarwal, Rahul; Halabi, Susan; Kelly, William Kevin et al. (2013) The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) ( Cancer 119:3636-43

Showing the most recent 10 out of 45 publications